Back to today’s briefing

Story perspectives

FDA Approves ENFLONSIA: 84% Drop in RSV Hospitalizations

6/10/2025

50 12

Summary

Story summary

The FDA has given the green light to Merck's ENFLONSIA (clesrovimab), a groundbreaking monoclonal antibody designed to shield infants from respiratory syncytial virus (RSV) during their crucial first season. Clinical trials showcased its impressive efficacy, slashing RSV-related hospitalizations by 84.3% and reducing medically attended infections by 60.5%. Expect ENFLONSIA to hit the market before the 2025-26 RSV season.

1 of 1

Story summary

The FDA has given the green light to Merck's ENFLONSIA (clesrovimab), a groundbreaking monoclonal antibody designed to shield infants from respiratory syncytial virus (RSV) during their crucial first season. Clinical trials showcased its impressive efficacy, slashing RSV-related hospitalizations by 84.3% and reducing medically attended infections by 60.5%. Expect ENFLONSIA to hit the market before the 2025-26 RSV season.